[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Uppsala University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":723},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,67,0,25,[9,76,109,136,168,200,235,258,282,306,333,356,386,419,443,473,501,527,547,563,593,625,651,668,693],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100636735","surgery-for-thumb-base-osteoarthritis-joint-replacement-vs-trapeziectomy-100636735",false,"NCT07569549","Surgery for Thumb Base Osteoarthritis: Joint Replacement vs. Trapeziectomy","BASTION - BASe of Thumb Osteoarthritis Management Non-inferiority Trial: Surgical Treatment of First Carpometacarpal Joint Osteoarthritis: A Comparison Between Joint Replacement and Trapeziectomy","BASTION","Inclusion Criteria:\n\n* Age 40-80 years at inclusion\n* CMC-joint osteoarthritis grade 1-3 (Eaton-Littler classification)\n* Rest pain or pain reducing hand function with indication for surgery\n* Insufficient relief from non-operative treatment for ≥3 months (orthosis, OTC analgesics, cortisone injection)\n* Eligible for both prosthesis and trapezectomy per including surgeon\n* Non-smoker or complete smoking cessation ≥6 weeks prior to surgery\n\nExclusion Criteria:\n\n* Previous surgery to thumb base or STT-joint\n* Ongoing chronic pain condition\n* Dementia or cognitive impairment\n* Trapezium height \\\u003C7 mm on plain radiograph\n* Active smoker\n* Osteoarthritis grade 4 (Eaton-Littler)","ALL","40 Years","80 Years",{"count":22,"type":23},84,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if the surgical method with total joint arthroplasty, (TOUCH joint prosthesis), is as good as or better than the traditional surgical method, trapezectomy, to treat thumb base joint osteoarthritis.\n\nThe main questions it aims to answer are:\n\nDoes surgery with total joint arthroplasty provide better power grip and pinch grip strength compared to traditional surgery?\n\nWhat is the long-term risk of complications for both methods?\n\nWhich method is more cost-effective for the healthcare system?\n\nResearchers will compare total joint arthroplasty (TOUCH) to trapezectomy (a procedure where a bone in the thumb base is removed) to see which method provides the best results for the patient.\n\nParticipants will:\n\nBe randomized to undergo either an operation with total joint arthroplasty or a trapezectomy.\n\nUndergo an initial evaluation and a health economic cost analysis after one year.\n\nAttend follow-up checkups at 2, 5, and 10 years post-surgery to evaluate long-term function and the durability of the prosthesis.",[29,30,31,32],"Thumb Osteoarthritis","Thumb Carpometacarpal Joint Osteoarthritis","Carpometacarpal (CMC) Joint Arthritis","Basal Thumb Osteoartrithis",[34,35,36,37,38,39,40,29,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62],"Thumb base arthroplasty","CMC joint","prosthesis","hand surgery","First Carpometacarpal Joint","Trapeziometacarpal Joint","Rhizarthrosis","Dual Mobility Prosthesis","Total Joint Replacement","Total Joint Arthroplasty","Ligament Reconstruction","Surgical Reconstruction","Randomized Controlled Trial (RCT)","Prospective Studies","Comparative Study","Prospective Study","Cost-Effectiveness Analysis","Cost-Benefit Analysis","Health Economics","Patient Reported Outcome Measures (PROMs)","Quality of Life (QoL)","Health-Related Quality of Life (HRQoL)","Return to Work","Grip Strength","Pinch Strength","QuickDASH","EQ-5D","Michigan Hand Outcomes Questionnaire (MHQ","Trapeziectomy","RECRUITING","2026-06-22",{"date":66,"type":67},"2026-06-25","ACTUAL",{"date":69,"type":23},"2026-07-01",{"date":71,"type":23},"2038-03",{"name":73,"class":74},"Uppsala University","OTHER",2,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100639220","shame-resilience-and-well-being-after-intimate-partner-violence-an-intervention-study-with-replicated-single-subject-design-100639220","NCT07618754","Shame, Resilience and Well-being After Intimate Partner Violence: an Intervention Study With Replicated Single-Subject Design.","EMBER-4","Inclusion Criteria:\n\n* subjected to IPV within 2 years prior to enrollment\n* capable of completing questionnaires using a mobile phone\n* intention to complete intervention\n* identifies as female\n\nExclusion Criteria:\n\n* ongoing severe IPV\n* ongoing severe substance use\n* psychosis\n* moderate to severe suicidality\n* ongoing psychological intervention in other facility","FEMALE","18 Years",{"count":86,"type":23},8,[26],"The EMBER protocol is a health care method that is designed to increase resilience, in order to improve well-being and overall health in women who have experienced violence by a partner. This study explores whether the EMBER intervention works in this way. Eight participants will take part in the EMBER program and complete questionnaires every week during the intervention. The researchers will compare the timeline for the intervention to how resilience levels change. They will also check whether changes in resilience are linked to changes in health and well-being.",[90,91],"Intimate Partner Violence","Resilience, Psychological",[93,90,94,95,96,97,98],"Single Case Design","Domestic Violence","Domestic Violence and Abuse","Resilience, psychological","Trauma","Well-Being","NOT_YET_RECRUITING","2026-05-25",{"date":102,"type":67},"2026-06-01",{"date":104,"type":23},"2026-06",{"date":106,"type":23},"2030-06",{"name":73,"class":74},1,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":108},"100640395","resilience-and-recovery-after-intimate-partner-violence---evaluation-of-the-ember-ipv-protocol-100640395","NCT07606586","Resilience and Recovery After Intimate Partner Violence - Evaluation of the EMBER-IPV Protocol","EMBER-3","Inclusion Criteria:\n\n* Women taking part of the EMBER intervention (phase A or C)\n* Subjected to IPV within the past 2 years prior to enrollment\n\nExclusion Criteria:\n\n* Ongoing severe intimate partner violence\n* Ongoing severe substance abuse\n* Severe mental health problems such as psychosis, suicidality",{"count":117,"type":23},150,"OBSERVATIONAL","The EMBER-protocol is an intervention used at the NCK clinic at Uppsala University Hospital with the purpose of helping women utilize their resilience and strengths in order to recover after intimate partner violence. This study is conducted in order to explore how health and resilience changes during the course of the EMBER-intervention. The participants are asked to complete questionnaires before, during and after the intervention.",[90,121,122,123,91],"Intimate Partner Violence Against Women","Shame","Domestic Abuse",[90,94,125,126,122,96,127],"domestic violence exposure","gender-based violence","resilience intervention","2026-05-18",{"date":130,"type":67},"2026-05-26",{"date":132,"type":23},"2026-05",{"date":134,"type":23},"2029-04",{"name":73,"class":74},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":118,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100637126","swedish-intensive-care-biobank-100637126","NCT07582601","SWedish Intensive Care Biobank","Hereditary Influence on Risk Factors for Severe Illness in a Swedish Intensive Care Biobank","SWIC-B","Inclusion Criteria:\n\n* Adults admitted to intensive care in Sweden\n\nExclusion Criteria:\n\n* Non adults\n* Not admitted to intensive care",{"count":145,"type":23},25000,"1 Year","The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. The main questions it aims to answer are:\n\nWhich genetic variants are associated with increased risk of critical illness from conditions such as infections, sepsis, and organ failure?\n\nCan circulating proteins and metabolites mediate the effect of genetic risk factors on the severity of illness?\n\nParticipants will:\n\nProvide blood samples at ICU admission and again 3-6 months after discharge Consent to genetic analysis and data linkage with national health registries\n\nHave their ICU treatment and outcomes followed using registry and clinical data\n\nThis study aims to build a national infrastructure for rapid sample collection and analysis that can also support research in future pandemics.",[149],"Any Condition Underlying Critical Illness",[151,152,153,154,155,156,157,158,159],"critical illness","shock","sepsis","heart failure","ards","acute kidney injury","infection","organ failure","intensive care","2026-05-11",{"date":162,"type":67},"2026-05-13",{"date":164,"type":23},"2027-01-01",{"date":166,"type":23},"2035-12-30",{"name":73,"class":74},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},"100619940","postoperative-acute-kidney-injury-in-children-undergoing-major-non-cardiac-surgery-100619940","NCT07351149","Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery","An International Multicentre Prospective Study of Postoperative Acute Kidney Injury in Hospitalized Paediatric Patients","POAKIDS","Inclusion Criteria:\n\n* Elective, urgent or emergency in-patient major non-cardiac surgical procedures performed under general anaesthesia with or without regional analgesia with a planned procedure duration of at least 60 minutes.\n* Paediatric patients (0-16 years old)\n\nExclusion Criteria:\n\n* Declined participation.\n* Ongoing renal replacement therapy\n* Acute Kidney Injury (according to KDIGO)\n* Known chronic kidney disease\n* Procedure involving surgery of the kidney\n* Procedures requiring clamping of blood flow to or from the kidney\n* Body weight \\\u003C2kg\n* Procedure involving contrast administration\n* Established rhabdomyolysis (CK-levels \\>1500 U\u002FL)","0 Years","16 Years",{"count":179,"type":23},2000,"This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery. Urinary biomarkers are intended to be evaluated as predictors of PO-AKI in the same subjects. The study employs modern standardized classifications for AKI to comprehensively address the issue of PO-AKI in children. Describing the incidence and identifying risk factors for PO-AKI will play a crucial role in developing preventive strategies aimed at reducing associated mortality and morbidity. Furthermore, investigating the relationship between urinary biomarkers of renal injury and PO-AKI will provide valuable insights into assessing postoperative renal function in paediatric patients, especially when repeated blood sampling is not feasible.",[182],"Acute Kidney Injury",[184,185,186,187,188,189,190,191],"Postoperative acute kidney injury","Pediatric kidney injury","Pediatric renal failure","Urinary biomarkers","Pediatric urinary biomarkers","Pediatric postoperative kidney injury","Pediatric anesthesia","Risk factors for pediatric acute kidney injury",{"date":193,"type":67},"2026-05-12",{"date":195,"type":67},"2026-03-01",{"date":197,"type":23},"2028-12-31",{"name":73,"class":74},13,{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":220,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":108},"100527265","promoting-sleep-to-alleviate-pain---arthroplasty-100527265","NCT06145516","Promoting Sleep to Alleviate Pain - Arthroplasty","Preoperative Sleep-promotion to Achieve Improved Postoperative Pain Control and Recovery: a Randomized, Controlled Trial","PROSAP-A","Inclusion Criteria:\n\n* age ≥18 years\n* insomnia severity index score \\>10\n* fulfill DSM-V criteria for persistent insomnia disorder\n* average pain numerical rating scale (NRS) score ≥4 (scale 0 - 10) and\u002For movement-related pain NRS score ≥4 after 5 minutes walking\n* scheduled to undergo primary (first-time, i.e., not revision surgery) TKA or THA due to osteoarthritis\n\nExclusion Criteria:\n\n* uncontrolled medical disorders\n* nightshift work\n* ongoing major depressive disorder, bipolar disorder, psychotic disorder, substance dependence\n* current history or high likelihood of primary sleep disorders (other than insomnia), including obstructive sleep apnea syndrome, narcolepsy, nocturnal myoclonus\n* severely impaired vision (precluding ability to take part of study interventions)","100 Years",{"count":210,"type":23},100,[26],"PROSAP-A is a perioperative randomized, controlled trial with a 12-month follow-up period after total knee arthroplasty (TKA) or total hip arthroplasty (THA), aiming to investigate both acute and long-term postoperative effects of preoperative sleep-promotion. Participants with clinically significant insomnia symptoms will be randomized to a brief, hybrid version of cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy, administered over a 4-week period, prior to surgery. The primary objective is to evaluate effects of preoperative sleep-promotion on acute postoperative pain control. Secondary objectives include evaluation of postoperative sleep, recovery, mental health, cognitive function and alterations in blood biomarkers.",[214,215,216,217,218,219],"Osteoarthritis, Knee","Osteoarthritis, Hip","Insomnia","Surgery","Pain, Postoperative","Postoperative Complications",[221,222,223,224,225,226],"osteoarthritis","total knee arthroplasty","total hip arthroplasty","insomnia","sleep disturbance","postoperative pain","2026-04-29",{"date":229,"type":67},"2026-05-06",{"date":231,"type":67},"2025-09-01",{"date":233,"type":23},"2030-12-01",{"name":73,"class":74},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":108},"100636081","postoperative-pain-in-infants-100636081","NCT07561047","Postoperative Pain in Infants","Postoperative Pain Assessment in Newborns Using Skin Conductance Measurement","Poppi","Inclusion Criteria:\n\n* Neonates admitted to the NICU\n* Undergoing surgical intervention\n* Receiving postoperative care at the study site\n\nExclusion Criteria:\n\n* Major heart surgery\n* No parental consent",{"count":210,"type":23},"This observational study aims to evaluate skin conductance monitoring as a continuous method for pain assessment in postoperative neonates. Pain assessment in newborns is challenging due to their inability to communicate, and current methods rely on intermittent observational scales such as the Neonatal Pain, Agitation and Sedation Scale (N-PASS) in combination with physiological parameters.\n\nSkin conductance reflects sympathetic nervous system activity and provides a continuous, objective measure of stress and pain. This study will investigate the correlation between skin conductance measurements and standard clinical pain assessment tools (N-PASS and vital parameters), as well as explore the potential analgesic effect of skin-to-skin care.\n\nThe study is conducted in a neonatal intensive care unit (NICU) setting where all monitoring and treatments are part of routine clinical care.",[246],"Postoperative Pain",[248,226,249,250],"skin conductance monitoring","neonate","preterm infant","2026-04-24",{"date":253,"type":67},"2026-05-01",{"date":102,"type":23},{"date":256,"type":23},"2029-06-01",{"name":73,"class":74},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":83,"minAge":84,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":108},"100611064","how-a-resilience-focused-intervention-is-perceived-by-women-subjected-to-domestic-violence-100611064","NCT07235722","How a Resilience-Focused Intervention is Perceived by Women Subjected to Domestic Violence","Exploring Resilience. A Qualitative Study of an Intervention After Intimate Partner Violence.","EMBER-2","Inclusion Criteria:\n\n* Enrolled in the EMBER intervention at the NCK outpatient clinic.\n\nExclusion Criteria:\n\n* Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.",{"count":267,"type":23},30,"At Uppsala University Hospital, there is an outpatient clinic for women subjected to intimate partner violence. In order to explore how patients experience the biopsychosocial resilience-based intervention in use at the clinic and how well the intervention fits the needs of the patients, 30 patients from different stages of their contact at the clinic and with diverse life situations and background are enrolled. The researchers will carry out individual in-person interviews, each lasting approximately 60 minutes, based on a semi-structured set of questions. The questions concern the participant´s life situation, resilience and self-perceived needs, how well the intervention has met those needs and how it was perceived by the participant. The interviews are audio-recorded and transcribed verbatim for thematic analysis.",[122,90,270,91],"Domestic Violence Exposure",[272,273,90,94,125,126,122,91],"Qualitative","interview","2026-04-08",{"date":276,"type":67},"2026-04-13",{"date":278,"type":67},"2026-04-07",{"date":280,"type":23},"2027-03",{"name":73,"class":74},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":290,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":108},"100608854","validation-of-the-swedish-translation-of-a-brief-shame-measure-the-external-and-internal-shame-scale-100608854","NCT07206966","Validation of the Swedish Translation of a Brief Shame Measure, the External and Internal Shame Scale","Validation of the Swedish Translation of a Brief Shame Measure, the External and Internal Shame Scale (EISS)","EMBER-1","Inclusion Criteria\n\n* Must be 18 years of age or above\n* Must be capable of communicating in Swedish\n* Participants in clinical samples must be patients at one of the clinics involved in the study.\n\nExclusion criteria\n\n* None.",true,{"count":292,"type":23},350,"Shame is a normal emotion that people sometimes have. Experiencing a lot of shame has however been found to have a link to ill mental and somatic health. Therefore it is of interest to have a brief way of measuring shame. External and Internal shame scale (EISS) is a questionnaire with 8 items that is available in several languages, but not yet in Swedish. The researchers have translated it to Swedish and will investigate how well the Swedish version works for measuring shame. 300 participants are enrolled via social media and asked to complete the EISS as well as two other scales for comparison. Participants are also asked about their age and gender. In addition 50 participants will be recruited from an outpatient clinic in order to check how the scale works in clinical settings. The researchers will use the answers to statistically calculate the scientific properties of the EISS.",[122],[296,297,122,298,299],"Psychometrics","Psychological Tests","Patient Health Questionnaire","Surveys and Questionnaires",{"date":276,"type":67},{"date":302,"type":67},"2025-10-23",{"date":304,"type":23},"2026-08",{"name":73,"class":74},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":317,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":332},"100632707","phase-2-the-hit-hard-and-hit-early-in-multiple-sclerosis-trial-100632707","NCT07517185","The HIt HArd and hiT Early in Multiple Sclerosis Trial","The HIt HArd and hiT Early in Multiple Sclerosis Trial - HiHat Trial A Phase 2 Study of Sequential Treatment With Rituximab and Cladribine for Relapsing-remitting Multiple Sclerosis","HiHat","Inclusion Criteria:\n\n* Diagnosis of RRMS according to the 2017 revised McDonald criteria,\n* With disease activity within the preceding year in the form of: a clinical relapse, and\u002For evidence of ≥2 T2 lesions on MRI scan, and or presence of gadolinium enhancing lesions on an MRI scan,\n* Age 18 - 50 years (inclusive) of age,\n* Disease duration ≤10 years (since MS diagnosis),\n* EDSS 0 - 5.5 (inclusive),\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of progressive MS,\n* Previous use of rituximab (or any other B-cell depleting monoclonal antibody) and\u002For cladribine,\n* Pregnant or lactating women,\n* Unwilling to use contraception during the treatment period and the first year after completing the treatment course,\n* Patients having contraindication for or otherwise not compliant with MRI investigations,\n* Simultaneous treatment with other immunosuppressive drugs,\n* Infection with human immunodeficiency virus (HIV),\n* Active, severe infections (e.g. hepatitis or tuberculosis),\n* Severe cardiac disorder,\n* Moderate or severe renal impairment (eGFR \\\u003C60).\n* Active malignancy,\n* No prior exposure to varicella virus,\n* Vaccination within 4 weeks of first dose of study medication,\n* Severe psychiatric condition.","50 Years",{"count":316,"type":23},60,[318],"PHASE2","The HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS). The study follows a prospective, open-label, single-arm design, with 60 RRMS patients receiving both treatments in a controlled regimen: two cycles of rituximab (1,000 mg each, biweekly) followed by two cycles of cladribine (30 mg per cycle for three days per cycle) spaced one month apart. Participants are monitored over 24 months through clinical assessments, MRI, and biomarker analyses. The primary objective is to evaluate whether the rate of serious adverse events (SAE) is acceptably low. Secondary objectives include assessing impacts on MRI lesion count, relapse rates, disability progression, quality of life, and safety.",[321],"Relapsing-remitting Multiple Sclerosis",[323,324],"rituximab","cladribine","2026-04-01",{"date":274,"type":67},{"date":328,"type":23},"2026-04-15",{"date":330,"type":23},"2030-12-31",{"name":73,"class":74},4,{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":24,"phases":342,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":355},"100553622","phase-3-assessment-of-short-immunotherapy-after-radical-surgery-of-high-risk-malignant-melanoma-100553622","NCT06488482","Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","A Prospective Randomized International Multicenter Study to Compare Short Versus Long Adjuvant Immunotherapy After Radical Surgery of Stage IIb-c, III and IV Cutaneous Malignant Melanoma (Grand SLAM)","Inclusion Criteria:\n\n1. Provision of written informed consent for participation.\n2. ≥ 18 years of age.\n3. Performance status ECOG\u002FWHO 0-1.\n4. Adequate organ functions as per standards for immunotherapy.\n5. Radical surgery for CMM (including acral) stage IIb-c, III (including in transit) and IV. Stage III CMM patients with unknown primary and stage IIb-c CMM patients who have not undergone sentinel node procedure are eligible.\n6. A complete physical examination within 28 days prior to randomization\n7. Previous adjuvant treatment with BRAF + MEK inhibitors is allowed.\n8. Neoadjuvant treatment with immunotherapy for two months (currently pembrolizumab every third weeks three times or nivolumab every fourth week two times) is allowed providing that a complete or near complete pathological response was not achieved and patients with clear progressive disease according to the pathology report are not eligible.\n9. All participants who have not received neo-adjuvant treatment must have disease-free status documented by radiological assessment within 28 days prior to randomization while 6 weeks is sufficient for neo-adjuvant treated patients.\n10. Participants must be off immunosuppressive doses of systemic steroids (\\>10 mg\u002Fday prednisone or equivalent) for a minimum of 14 days prior to study drug administration.\n11. Sufficient renal function for radiological assessments with i.v. contrast.\n12. Peri-operative radiation therapy is allowed.\n13. Patients who experience a locoregional lymph node relapse, i.e. stage III disease or operable stage IV at a time-point later than primary diagnosis are welcome to participate.\n\nExclusion Criteria:\n\n1. The patient is, in the opinion of the investigator, assessed as unfit to receive systemic adjuvant treatment.\n2. Serious and\u002For uncontrolled medical disorder that in the opinion of the investigator is contraindicated.\n3. An active, known, or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism requiring hormone replacement only and skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are eligible.\n4. Life-expectancy less than 2 years due to concurrent disease (e.g., cardiac disease and liver cirrhosis).\n5. Inability to provide informed consent or refusal to do so.\n6. Inability to comply with the study protocol.\n7. Participation in other clinical trials interfering with the current study protocol.\n8. Existing or previous malignancies within the past 5 years (except for in situ breast and in situ cervical cancer, melanoma in situ, malignant melanoma, non-melanoma skin cancer and low risk prostate cancer).\n9. Pregnancy or planned pregnancy.\n10. Ocular and mucosal melanoma.",{"count":341,"type":23},1792,[343],"PHASE3","1. Rational Every year, around 5,000 people in Sweden are diagnosed with malignant skin melanoma. In the early stages of malignant skin melanoma, the chance of cure with surgery is very good. At a later stage, when the melanoma has become thick and\u002For has spread, the risk of recurrence is greater despite radical surgery. Therefore, in these cases (even in cases of recurrence after radical surgery), additional treatment with immunotherapy is often given, as it has been shown to reduce the risk of recurrence. Immunotherapy is given for one year based on previous research studies, but it has not been investigated whether a shorter treatment period has the same effect. The hypothesis is that six months of treatment is equally effective, which would have several advantages. The main advantage of a shorter treatment period is that the risk of severe side effects is reduced. A shorter treatment period also means fewer hospital visits for patients. In addition, significant drug costs and other healthcare resources could be saved.\n2. Aim\u002Fobjective The aim of the study is to investigate whether 6 months of treatment with immunotherapy, in addition to radical surgery, for malignant skin melanoma at high risk of recurrence, is as effective in preventing recurrence as 12 months of treatment.\n\n   Secondary objectives:\n\n   To investigate overall survival after 6 versus 12 months of treatment with immunotherapy.\n\n   To investigate the health economic effects of a shorter treatment.\n3. Primary endpoints The two primary endpoints of the study are relapse-free survival (RFS) and distant metastatic-free survival (DMFS) and they will be analyzed for the first time in the interim analysis conducted after 2\u002F3 of the estimated number of patients have been included in the study.\n4. Secondary outcome measures Overall survival will be analyzed for the first time in the interim analysis. Health economic calculations are planned only at the final stage of the study.\n5. Study design This is a randomised phase 3 study, with the aim of showing that treatment in the experimental arm (6 months of immunotherapy) is not inferior to the treatment in the standard arm (12 months of immunotherapy). Patients will be followed up to five years. The visits in the study follow clinical routine.\n6. Study population Patients aged ≥18 years undergoing radical surgery for stage IIb-c, III or IV cutaneous malignant melanoma, with a WHO general condition score of 0-1 and deemed tolerable to immunotherapy.\n7. Study treatment The study treatment consists of immunotherapy according to clinical routine, currently nivolumab or pembrolizumab given intravenously for either 6 months (experimental treatment) or 12 months (standard treatment). For patients receiving neoadjuvant treatment (additional treatment before surgery), the neoadjuvant treatment time is added to the adjuvant treatment time (additional treatment after surgery) to give a total treatment time of 6 or 12 months. Treatment is followed up according to routine, with imaging (CT or PET-CT) at baseline and after 6 months and at an additional time beyond clinical routine, after 36 months, as well as medical examination at baseline, 6, 12, 18, 24 and 36 months. In case of any signs of relapse, additional examinations are performed as needed. If relapse is detected, the patient is discussed at a local multidisciplinary conference to select the best available treatment for each patient. All study patients are followed for survival status for up to five years.\n8. Risk-benefit and ethical issues If this study shows that a shorter treatment period is as effective as the current one-year treatment, it would greatly benefit patients by reducing the risk of side effects and reducing the number of hospital visits. It would also save healthcare resources, which could then be used in other areas. The Swedish Melanoma Patient Association (Melanompatientföreningen) has been consulted and is positive about the study, however they expect that patients may be reluctant to participate for fear of receiving inferior treatment.\n\nHowever, none of the pivotal studies conducted to date have shown that adjuvant systemic treatment of patients with malignant melanoma significantly prolongs overall survival, but its routine use is based on prolonged relapse-free survival. In addition, a recent cohort study indicated no survival benefit after the introduction of immunotherapy.\n\nTo ensure that the experimental arm is not clearly inferior to the standard arm, an interim analysis will be conducted in this study (see above). It is worth mentioning that similar studies to Grand SLAM have been conducted in breast and colon cancer where additional treatment after surgery has been introduced as it not only reduces the risk of recurrence but also prolongs overall survival. These studies have shown that shorter treatment is equally effective.",[346],"High-risk Melanoma","2026-03-05",{"date":349,"type":67},"2026-03-09",{"date":351,"type":67},"2024-12-19",{"date":353,"type":23},"2033-09",{"name":73,"class":74},26,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":366,"studyType":118,"phases":4,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":385},"100628438","robotic-assisted-pedicle-screw-placement-in-spine-surgery-100628438","NCT07461636","Robotic-Assisted Pedicle Screw Placement in Spine Surgery","ROBOTICSS - Robotic-Assisted Pedicle Screw Placement in Spine Surgery: A Multicenter Prospective Observational Study","ROBOTICSS","Inclusion Criteria:\n\n* Treatment with pedicle screws in the cervical, thoracic, lumbar spine and\u002For sacrum.\n* All ages and spinal diagnoses\n\nExclusion Criteria:\n\n* Treatment without pedicle screws",{"count":365,"type":23},7200,"5 Years","This prospective multicenter observational cohort study evaluates robotic-assisted pedicle screw placement compared with non-robotic-assisted techniques in spinal surgery. Primary objectives include screw placement accuracy, operative learning curve, and reoperation rate within 2 years.",[369],"Pedicle Screw Fixation of Spine",[371,372,373,374,375,217,376],"Robotic assisted","Pedicle screws","Spinal implants","Spinal disorder","Spine","Surgical technique","2026-03-04",{"date":379,"type":67},"2026-03-10",{"date":381,"type":67},"2026-02-02",{"date":383,"type":23},"2035-02-02",{"name":73,"class":74},9,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":290,"sex":18,"minAge":394,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":404,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":75},"100627383","combining-mental-health-and-parenting-interventions-to-improve-child-wellbeing-among-refugee-families-in-tanzania-100627383","NCT07447921","Combining Mental Health and Parenting Interventions to Improve Child Wellbeing Among Refugee Families in Tanzania","Combining Mental Health and Violence Prevention Interventions to Enhance Child Wellbeing Under Adversity - Study Protocol for a Three-arm, Cluster-randomized, Superiority Trial With Primary Caregivers in Nyarugusu Refugee Camp, Tanzania (WEMA Trial)","WEMA","Inclusion Criteria:\n\n* Families residing in Nyarugusu Refugee Camp, Tanzania\n* Congolese refugee origin (for cultural and linguistic homogeneity)\n* Two primary caregivers (one male, one female) aged 18 years or older, caring for at least two children aged 7-10 years\n* Ability to speak and understand Kiswahili\n* Willingness to provide informed consent (and child assent)\n* No plans to leave the camp within the next 12 months\n\nExclusion Criteria:\n\n* Caregivers currently enrolled in other mental health or parenting programs\n* Caregivers displaying imminent suicide risk, psychosis, or severe cognitive impairment that would impede participation\n* Children with known developmental disabilities reported by caregivers","7 Years",{"count":396,"type":23},1296,[26],"The goal of this clinical trial is to learn whether improving caregivers' mental health and parenting practices can enhance child wellbeing among Congolese refugee families living in the Nyarugusu Refugee Camp, Tanzania. The WEMA trial (\"Wellbeing through combined Evidence-based tools for Mental health and Attuned parenting\") is a three-arm, family-level cluster-randomized, controlled superiority trial involving 324 families (approximately 648 children aged 7-10 years and their two primary caregivers). Participants and intervention facilitators will know which program a family receives, but outcome assessors (enumerators) will not know group assignment.\n\nThe main questions it aims to answer are:\n\n* Does Self-Help Plus (SH+), a World Health Organization (WHO) group stress-management program, improve children's emotional and behavioral functioning at 12 months post-intervention, compared with usual care?\n* Does adding Interaction Competencies with Children for Parents (ICC-P), a participatory parenting program, after SH+ further improve children's emotional and behavioral functioning at 12 months post-intervention, compared with SH+ alone?\n\nResearchers will compare (1) Usual Care, (2) SH+, and (3) SH+ followed by ICC-P to see whether SH+ improves outcomes versus usual care, and whether SH+ followed by ICC-P provides additional benefits beyond SH+ alone.\n\nParticipants will:\n\n* Be assigned by chance by family clusters to one of three groups: Usual Care, SH+, or SH+ followed by ICC-P.\n* Receive either (a) information about available psychosocial and mental health services (Usual Care), (b) SH+ (five group sessions delivered by trained non-specialists), or (c) SH+ followed by ICC-P (a four-day participatory parenting training to strengthen positive parenting and reduce harsh discipline).\n* Complete study assessments at baseline, 3 months, and 12 months post-intervention.\n\nThe primary outcome is children's emotional and behavioral functioning, measured using the Pediatric Symptom Checklist-17 (PSC-17) at 12 months post-intervention. Secondary outcomes include children's wellbeing and quality of life, as well as caregivers' mental health, well-being, and parenting practices. Additional exploratory outcomes will also be assessed, including measures collected from caregivers and behavioral tasks with children.\n\nThe trial is implemented by Uppsala University in collaboration with the Dar es Salaam University College of Education (DUCE) and partners, with funding from the Swedish Research Council (grant no. 2022-02476).",[400,401,402,403],"Mental Health","Socio-emotional Well-being","Functioning, Psychosocial","Parenting Behavior",[405,406,407,408,409,410,411],"Mental health","Child development","Parenting","Refugees","Self-Help Plus","Interaction Competencies with Children - for Parents","Tanzania","2026-02-25",{"date":377,"type":67},{"date":415,"type":23},"2026-03-15",{"date":417,"type":23},"2027-07",{"name":73,"class":74},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":290,"sex":18,"minAge":84,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":108},"100603576","dietary-impact-on-sleep-rhythms-and-related-physiology-100603576","NCT07138313","Dietary Impact on Sleep, Rhythms and Related Physiology","Inverkan av Kost pa Dygnsrytmer Och Amnesomsattning","Inclusion Criteria:\n\n* Age 18-32 yr\n* Healthy (self-reported) and not on chronic medication\n* BMI 18-27 kg\u002Fm2 (and waist circumference \\\u003C102 cm), and weight stable (less than 5% body weight change in the past 6 months)\n* Non-smoker and non-nicotine user\n* Regular sleep-wake pattern, with sleep duration of 7-9.25 hrs per night\n* Regular exercise habits the last 2 months\n* Regular daily meal pattern with 3 main meals\n\nExclusion Criteria:\n\n* Major or chronic illness, e.g. diabetes, renal disease or inflammatory bowel disease\n* Current or history of endocrine or metabolic disorders\n* Psychiatric or neurological disorders (e.g. bipolar disorder, epilepsy)\n* Frequent gastrointestinal symptoms\n* Chronic medication\n* Any sleep disorder (including recent or chronic symptoms of insomnia)\n* Shift work in the preceding three months or for a long duration\n* Extreme chronotype or physical activity patterns\n* Time travel over two time zones in the preceding month\n* Too much weight gain or weight loss in the preceding 6 months (±5% body weight in past 6 months)\n* Any issues with or allergies against the provided food items\n* Recent major dietary changes or adoption of specific dietary regimens\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n* Use of illicit drugs or substances of abuse","32 Years",{"count":428,"type":23},24,[26],"Sleep and metabolism are closely interconnected, and emerging evidence suggests that dietary composition may influence both sleep quality and key physiological functions such as glucose regulation, cardiovascular activity, and hormonal signaling. This study aims to investigate how a Western-style unhealthy diet versus a healthier, fiber-rich diet affects objective and subjective sleep measures, 24-hour physiological parameters, and a range of biomarkers related to cardiometabolic, neurodegenerative, and gut microbial function.",[432,433,434],"Sleep","Diet Interventions","Circadian Rhythm","2026-02-03",{"date":437,"type":67},"2026-02-04",{"date":439,"type":67},"2025-09-22",{"date":441,"type":23},"2027-12-31",{"name":73,"class":74},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":290,"sex":18,"minAge":4,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":454,"conditions":455,"keywords":459,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":108},"100622310","biomarkers-of-brain-injury-in-children-with-brain-tumors-100622310","NCT07381959","Biomarkers of Brain Injury in Children With Brain Tumors","Biomarkörer för hjärnskada Hos Barn Med hjärntumör","BiomarkCBT","Inclusion Criteria, Group A (treated with radiation):\n\n* Age 0-17 years old, AND\n* Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND\n* Referred for radiotherapy at Skandion Clinic in Uppsala and\u002For at their local hospital (in some cases), with\u002Fwithout the addition of other cancer treatments.\n\nInclusion Criteria, Group B (treated without radiation\u002Fradiation naive):\n\n* Age 0-17 years old, AND\n* Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for optic pathway glioma in neurofibromatosis type 1 and germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND\n* Not referred to radiotherapy and treated with\u002Fwithout the addition of other cancer treatments.\n\nInclusion Criteria, Group C (healthy control group):\n\n* Age 0-17 years old at time of recruitment\n\nExclusion Criteria, Groups A + B:\n\n* Diagnosed with a tumor only in the spinal cord (solitary spinal tumor).\n* Diagnosed with a tumor considered palliative already at diagnosis (e.g., diffuse intrinsic pontine glioma)\n\nExclusion Criteria, Group C:\n\n* Have diagnosis of chronic disease that requires continuous medication.\n\nExclusion Criteria, all groups:\n\n* Unable to provide informed consent due to language difficulties.","17 Years",{"count":453,"type":23},560,"The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is:\n\nCan investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors?\n\nResearchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers.\n\nParticipants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.",[456,457,458],"Brain Tumor","Childhood Cancer","Childhood Brain Tumor",[460,461,462,463,464,465],"Radiotherapy","Cranial radiation therapy","Plasma biomarkers","Extracellular vesicles","Proteomics","Childhood brain tumor","2026-01-28",{"date":381,"type":67},{"date":469,"type":67},"2021-08-01",{"date":471,"type":23},"2031-12-31",{"name":73,"class":74},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":332},"100613962","pancreatic-neuroendocrine-tumour---optimal-surgical-debulking-or-not-100613962","NCT07273409","Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not","PANcreatic Neuroendocrine Tumour - Optimal Surgical Debulking Or Not (PANTODON). A Prospective, Two Armed, Parallel, Randomised, Controlled International Multicentre Study on WHO Grade 1-2, Stage 4 Pancreatic NET","PANTODON","Inclusion Criteria:\n\n* Pan- NET, ENETS\u002FAJCC stage 4 determined by CT or PET\u002FCT\n* Primary tumour or metastases confirmed as Pancreatic NET GI-WHO grade 1-2 pan-NET by histology or cytology\n* Age ≥ 18 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Subject not fit for surgery due to comorbidity or advanced age (reason to be specified)\n* Risk of surgery deemed too high by MDT or Surgeon (reason to be specified)\n* Previous surgery for pan-NET.\n* Hormonal symptoms caused by a functional pan-NET, not controllable by medical therapy, indicating debulking surgery.\n* Previously included in the current study.\n* Pregnancy\n* The study subject does not fit into either STRATA: a) STRATUM 1: Less than 70% of the total tumour volume can be debulked, b) STRATUM 2: no FDG-PET avid disease is observed OR all (100%) FDG-PET avid tumour is not resectable.\n* Other reason in the opinion of the Principal Investigator (reason to be specified).",{"count":482,"type":23},200,[26],"Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas\u002Fglucagonomas\u002FVIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate.\n\nThis is a prospective, two armed, parallel, randomised, controlled, international multi-centre study, aiming to investigate if a near-total tumour debulking (intervention) in metastatic (stage 4) GI-WHO grade 1-2 pan- NET, with or without oncologic treatment, is superior to oncologic treatment alone (control), with regards to overall survival, health-related quality of life, participant performance status, time until hospitalisation, adverse event characteristics and cost in the short and long term.",[486],"Pancreatic Neuroendocrine Tumor",[488,489,490,491,492],"Pan-NET","Stage 4","Debulking surgery","Non-functional Pan-NET","GI-WHO grade 1-2 Pan-NET","2026-01-21",{"date":495,"type":67},"2026-01-22",{"date":497,"type":67},"2026-01-09",{"date":499,"type":23},"2033-05-31",{"name":73,"class":74},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":146,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":511,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":108},"100620058","open-tap-block-in-pediatric-abdominal-surgery-100620058","NCT07352683","Open TAP-block in Pediatric Abdominal Surgery","TAP-blockad Vid öppen Bukkirurgi Hos Barn","Inclusion Criteria:\n\n* Age 1-15 years\n* Scheduled for elective or acute open adominal surgical procedure\n\nExclusion Criteria:\n\n* chronic abdominal pain\n* known allergy to local analgetic\n* Stage 4 renal failure\n* psychiatric ailnment","15 Years",{"count":510,"type":23},88,[26],"The goal of this trial is to evaluate an open TAP-block vs continuous administration of local anestetic via a wound catheter for postoperative pain management in patients 1-15 years of age undergoing open abdominal surgery.",[514],"Pain Management After Surgery",[516,517,518],"pediatric","TAP-block","postoperative pain management","2026-01-12",{"date":521,"type":67},"2026-01-20",{"date":523,"type":67},"2025-12-01",{"date":525,"type":23},"2030-01-01",{"name":73,"class":74},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":534,"targetDuration":536,"studyType":118,"phases":4,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":108},"100555441","defining-volume-status-in-sepsis-with-extracellular-water-measurement-100555441","NCT06512129","Defining Volume Status in Sepsis With Extracellular Water Measurement","Phenotypes in Sepsis - Extracellular Water for Volume Status Characterization","Inclusion Criteria:\n\n* Adults with sepsis.\n\nExclusion Criteria:\n\n* Pregnancy, other than sepsis known cause of shock.",{"count":535,"type":23},20,"7 Days","The goal of this observational study is to learn about the influence of extracellular water on volume status in adult sepsis patients presenting with hemodynamic instability. The main question it aims to answer is:\n\n• Can measurement of extracellular water (MoistureMeterD, Delfin Technologies Ltd, Kuopio, Finland) contribute to the description of hemodynamic instability in adult sepsis patients.\n\nPatients with sepsis admitted to intensive care will receive standard care with the addition of measurement of extracellular water.",[539],"Sepsis",{"date":541,"type":67},"2026-01-14",{"date":543,"type":67},"2025-03-01",{"date":545,"type":23},"2027-12-01",{"name":73,"class":74},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":290,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":558,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":562,"locationsCount":108},"100341076","inflammatory-mediators-of-acute-kidney-injury-in-intensive-care-100341076","NCT03720860","Inflammatory Mediators of Acute Kidney Injury in Intensive Care","Prospective Studie of Inflammatory Markers in Urine, Plasma and Sputum Associated With Acute Kidney Injury","PronMed","Inclusion Criteria:\n\nPatients admitted to the intensive\u002Fpost operative care unit\n\n* with septic shock or\n* post major surgery or\n* after intoxication with a chemical compund\n\nExclusion Criteria:\n\n* Pregnancy or\n* Breast feeding or\n* Chronic kidney disease or\n* intoxication with nephrotoxic compund or\n* lack of informed consent",{"count":210,"type":23},"Acute kidney injury (AKI) affects more than 50% of patients admitted to the intensive care unit. The most common underlying cause is sepsis. Severe AKI in combination with sepsis is associated with high mortality. The mechanisms for sepsis-induced AKI are largely unknown. Our hypothesis is that the inflammatory response to an infection cause collateral damage to host tissue and contributes to the development of AKI. In this study we want to investigate the presence of novel inflammatory mediators in patients with sepsis, patients subjected to major surgery (sterile inflammation) and non-inflamed patients and correlate their levels with the risk for AKI.",[539,217,182],{"date":519,"type":67},{"date":560,"type":67},"2018-01-01",{"date":132,"type":23},{"name":73,"class":74},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":572,"briefSummary":573,"conditions":574,"keywords":580,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":592},"100593243","treating-emergency-laparotomy-incisions-with-negative-pressure-wound-therapy-100593243","NCT07003906","Treating Emergency Laparotomy Incisions With Negative Pressure Wound Therapy","TELIN","Inclusion Criteria:\n\n* ≥18 years old\n* Written informed consent\n* \\>10 cm midline incision with primary skin closure\n* Emergency laparotomy\n\nExclusion Criteria:\n\n* Not able to consent (e.g. dementia, impaired cognitive function, unconscious)\n* Subjects not possible to follow up as assessed by the Investigator\n* Allergy to dressing material\n* Pregnancy or breastfeeding (females of childbearing potential)\n* Previous enrolment in the current study\n* Expected reoperation with 28 days of index laparotomy\n* Emergency laparotomy within 3 months",{"count":571,"type":23},720,[26],"The goal of this clinical trial is to investigate Negative Pressure Wound Therapy (NPWT) in adults undergoing emergency laparotomy. The main question it aims to answer is:\n\nDoes NPWT decrease wound complications?\n\nResearchers will compare it against regular dressings to see if NPWT is superior.",[575,576,577,578,579],"Surgical Incision","Wound Dehiscence","Surgical Site Infection","Incisional Hernia","Quality of Life",[581,582,583],"emergency surgery","negative pressure wound therapy","randomised controlled trial","2025-12-18",{"date":586,"type":67},"2025-12-26",{"date":588,"type":67},"2025-12-16",{"date":590,"type":23},"2035-12",{"name":73,"class":74},6,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":24,"phases":604,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":624},"100591487","the-scandinavian-displaced-lateral-clavicle-trial-100591487","NCT06981065","The Scandinavian Displaced Lateral Clavicle Trial","The Scandinavian Displaced Lateral Clavicle Trial (ScanDiLaC) - A Multicentre, Pragmatic, 12-Month, Non-inferiority, Randomized Controlled Trial","ScanDiLaC","Inclusion Criteria:\n\n\\- Displaced extraarticular lateral clavicle fracture (type II or V according to the modified Neer classification)\n\nExclusion Criteria:\n\n* Pathological fracture\n* Open fracture\n* Neurovascular injury\n* Same-time fracture in the upper extremity\n* Polytrauma\n* Contraindications to surgery and\u002For anesthesia\n* Unable to give informed consent\n* Inability to complete follow-up","65 Years",{"count":603,"type":23},96,[26],"A multicentre multinational RCT to investigate whether non-surgical treatment is non-inferior to surgical treatment for displaced extraarticular lateral clavicle fractures in adults.",[607],"Clavicle Fracture",[609,610,611,612,613,614,615],"Displaced lateral clavicle fracture","Non-surgical","Surgical","PROMs","Health economy","Non-inferior","Complications","2025-12-09",{"date":618,"type":67},"2025-12-10",{"date":620,"type":67},"2025-09-17",{"date":622,"type":23},"2029-12-31",{"name":73,"class":74},11,{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":24,"phases":634,"briefSummary":636,"conditions":637,"keywords":639,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":199},"100611158","phase-4-pivmecillinam-as-oral-step-down-treatment-for-escherichia-coli-febrile-urinary-tract-infection-versus-standard-of-care-100611158","NCT07236944","Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care: A Randomized Controlled Non-Inferiority Multicenter Trial","PIVOT","Inclusion Criteria:\n\n1. ≥18 years of age.\n2. Diagnosis of fUTI, defined as i) fever ≥ 38°C and ii) at least one of the following: flank pain or pelvic pain, nausea or vomiting, dysuria, urinary frequency or urgency, and costovertebral angle tenderness on physical examination.\n3. Growth of E. coli in urine with antimicrobial susceptibility to mecillinam.\n4. Adequate intravenous antibiotic treatment for fUTI (defined below) for 2 days to which the isolated E. coli is determined susceptible.\n5. Defervescence and hemodynamic stability for at least 24 hours, according to the responsible physician.\n6. Planned treatment with one of the following antibiotics, should the patient be randomized to the standard-of-care arm. Intravenous antibiotics: 1) Penicillins; ampicillin, piperacillin\u002Ftazobactam, ≥2) cephalosporins; cefotaxime, cefuroxime, ceftriaxone, 3) carbapenems; ertapenem, imipenem, meropenem, 4) monobactams; aztreonam, 5) aminoglycosides; amikacin, gentamicin, tobramycin, 6) other; fosfomycin. Oral antibiotics: 1) ciprofloxacin, 2) trimethoprim-sulfamethoxazole, 3) amoxicillin or amoxicillin\u002Fclavulanic acid provided that the isolated E. coli is determined susceptible according to the EUCAST-breakpoint for systemic infections, i.e., MIC ≤ 8 mg\u002Fl, and high dosing is used (≥750 mg amoxicillin x 3 and ≥750 mg amoxicillin\u002F125 mg clavulanic acid x 3, respectively) and 4) tebipenem (if approved by the EMA).\n7. Signed informed consent.\n\nExclusion Criteria:\n\n1. Adequate intravenous antibiotic treatment for \\> 4 days prior to randomization or other adequate (microbiologically active) oral antibiotic treatment for the same fUTI episode prior to recruitment.\n2. Growth of other bacterial species than E. coli, or fungi, in urine.\n3. Contraindication for pivmecillinam (e.g. allergy).\n4. Clinical suspicion of bacterial prostatitis.\n5. Renal abscess.\n6. Kidney transplant.\n7. Myelosuppressive disorder with neutrophil count \\\u003C 0.5 x 10(9)\u002FL at randomization.\n8. Planned antibiotic treatment for fUTI \\> 14 days.\n9. Likely to be prescribed antibiotic prophylaxis after treatment.\n10. Other intravenous or oral antibiotic treatment; ongoing or planned during the follow-up period (i.e. until 28 days after EOT for fUTI).\n11. Severe renal impairment (eGFR \\\u003C 20 mL\u002Fmin) at randomization.\n12. Morbid obesity (BMI \\> 40 kg\u002Fm2).\n13. Pregnancy or breastfeeding.\n14. Unlikely to follow instructions or the study protocol.\n15. Previous participation in the study.\n16. If consenting to microbiome analysis: i) contraindication for ciprofloxacin (e.g. allergy), ii) unlikely to be able to provide fecal samples per protocol, iii) treatment with antibiotics in the past 3 months before the current fUTI episode, iv) chronic intestinal disease or previous surgery in the gastrointestinal tract.\n17. If consenting to pharmacokinetic analysis: expected difficulties in providing blood and urine samples per protocol.",{"count":453,"type":23},[635],"PHASE4","The goal of this clinical trial is to learn if oral treatment with pivmecillinam is effective to treat febrile urinary tract infections in adult patients. Hospitalized patients who have received 2-4 days of intravenous antibiotic therapy for febrile urinary tract infections, and have responded to treatment, will be randomized to either pivmecillinam or standard treatment (other oral or intravenous antibiotics).\n\nThe main question the study aims to answer is if oral follow-up with pivmecillinam is as effective as standard treatment. Patients will be evaluated for clinical response (resolution of fever and urinary tract symptoms) and microbiological response (no growth of bacteria in urine) 7 and 28 days after the end of treatment. Patients will also be asked about side effects. Some of the participants will also be examined for changes in the gut microbiome and drug exposures in blood and urine.\n\nParticipants will:\n\n1. Keep a patient diary to record antibiotic intake, body temperature, urinary tract symptoms, and suspected side effects until 7 days after end of treatment.\n2. Participate in phone interviews 7 and 28 days after end of treatment to assess clinical response.\n3. Provide urine samples 7 and 28 days after end of treatment to evaluate microbiological response.\n4. A subgroup (60 patients) will provide fecal samples at five time-points over three months to assess antibiotic-induced changes in the gut microbiome.\n5. A subgroup (30 patients) treated with to pivmecillinam will provide blood and urine samples to determine the pharmacokinetics of mecillinam during one dosing interval.",[638],"Febrile Urinary Tract Infection",[640,641,642],"Urinary Tract Infection","Pivmecillinam","Escherichia coli","2025-12-08",{"date":645,"type":67},"2025-12-17",{"date":647,"type":23},"2025-12",{"date":649,"type":23},"2029-03",{"name":73,"class":74},{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":658,"conditions":659,"keywords":661,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":662,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":332},"100412190","betalactam-pharmacokinetics-in-endocarditis-patients-100412190","NCT04647331","Betalactam Pharmacokinetics in Endocarditis Patients","Inclusion Criteria:\n\n* Verified or suspected left or right sided endocarditis in native or prosthetic valve\n* Intravenous antibiotic therapy with either ampicillin, penicillin G, cefotaxime or cloxacillin\n* Signed informed consent to participate in study\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Ongoing dialysis",{"count":117,"type":23},"Infectious endocarditis (IE) is associated with mortality rates of 10-12%. Adequate antibiotic therapy is crucial for survival and is administered in high doses due to the severity of the disease. In most cases, beta-lactam antibiotics (e.g. ampicillin, penicillin G, cefotaxime or cloxacillin) are employed. A number of patient characteristics, such as age, body weight, and renal function) influence the pharmacokinetics of these drugs. Yet, the interindividual variability is poorly understood meaning that a large proportion of patients are at risk of subtherapeutic or excessive drug concentrations that might result in treatment failure or side effects, respectively.\n\nIn the present study, data will be collected on antibiotic concentrations in patients treated with beta-lactams for infectious endocarditis as well as patient characteristics and treatment outcomes. A mathematical model will be developed to determine which patient factors determine drug pharmacokinetics. Based on this model, predictions will be made by mathematical simulations on which dosing regimens are optimal for individual patients to ensure therapeutic and non-toxic drug concentrations. In total, 150 patients will be included at four University Hospitals in Sweden; Uppsala University Hospital, Sahlgrenska University Hospital in Gothenburg, Skåne University Hospital in Lund and Karolinska University Hospital in Stockholm. Following informed consent to participate blood samples will be collected at 6 time-points during a dose interval and then at 3 time-points weekly during the full treatment episode (maximum 6 weeks).",[660],"Infective Endocarditis",[660],{"date":645,"type":67},{"date":664,"type":67},"2021-06-01",{"date":666,"type":23},"2025-12-31",{"name":73,"class":74},{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":18,"minAge":84,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":24,"phases":677,"briefSummary":678,"conditions":679,"keywords":683,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":691,"leadSponsor":692,"locationsCount":4},"100613886","comparing-act-recuperation-and-act-plus-vocational-support-for-clinical-burnout-100613886","NCT07272421","Comparing ACT, Recuperation, and ACT Plus Vocational Support for Clinical Burnout","A Three-Arm Randomized Controlled Trial Comparing Online ACT, Recuperation, and ACT Plus Vocational Support for Clinical Burnout","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-reported or clinically verified symptoms consistent with clinical burnout (e.g., pronounced fatigue, cognitive difficulties, and reduced stress tolerance following prolonged psychosocial stress)\n* Currently on ≥25% sick leave and experiencing significant functional impairment in work or daily life due to these symptoms\n* Stable occupation or engagement (employment or studies)\n* Ability to read and write Swedish\n* Daily access to the internet\n\nExclusion Criteria:\n\n* Sick leave \\> 2 years for the current episode\n* Severe acute psychiatric conditions, including: severe depression, bipolar disorder, untreated PTSD, schizophrenia, or other psychotic disorders\n* Current substance abuse\n* Active suicidal ideation (as assessed during clinical evaluation)",{"count":676,"type":23},210,[26],"This study compares three different online psychological treatments for people with clinical burnout (stress-related exhaustion) who are on sick leave or have major difficulties coping at work or in daily life. Many patients with burnout receive broad, recuperation-focused interventions (rest, stress reduction, lifestyle changes), but there is still no clearly evidence-based treatment or agreed clinical model. It is also known that returning to work can be difficult, and there is a need for more structured support.\n\nIn this trial, 210 adults in Sweden with clinical burnout will be randomly assigned to one of three 10-week, internet-based treatments:\n\nOnline Acceptance and Commitment Therapy (ACT) A structured, values-based CBT approach that focuses on helping participants clarify what matters to them, relate differently to difficult thoughts and feelings, and gradually re-engage in meaningful activities despite exhaustion.\n\nOnline Recuperation-focused treatment An active comparison condition that emphasizes rest, recuperation, and healthy daily routines. It provides psychoeducation and practical tools for sleep, relaxation, physical activity, pacing, and balance in everyday life, but does not include ACT-specific methods such as exposure or values work.\n\nOnline ACT plus Vocational Support The same ACT program as in group 1, together with three additional sessions with a licensed psychologist focused on work. These sessions help the participant identify work-related barriers, plan a gradual return-to-work (RTW), and formulate a written RTW plan that can be shared with the employer and treating physician.\n\nAll three treatments are delivered via a secure digital platform. Participants work through weekly online modules, receive written feedback from a therapist, and have three video sessions during the 10-week period. Clinical psychology students in their final semester deliver the ACT and recuperation treatments, and licensed psychologists deliver the ACT + vocational support condition.\n\nThe study has two primary aims:\n\n1. to test whether online ACT reduces self-rated burnout symptoms more than the recuperation-focused treatment at the end of treatment, and\n2. to test whether adding structured vocational support to ACT reduces the total number of registered sick-leave days in the year after treatment, compared with ACT alone.\n\nKey secondary outcomes include perceived stress, depression, anxiety, insomnia, everyday memory problems, quality of life, functional impairment, treatment response and remission, treatment credibility and satisfaction, and cost-effectiveness. Outcomes are measured before treatment, weekly during treatment (for selected measures), immediately after treatment, and at 6- and 12-month follow-ups. Sick-leave data are obtained from the Swedish Social Insurance Agency.\n\nTo be eligible, participants must be 18 years or older, have symptoms consistent with clinical burnout (including pronounced fatigue and reduced stress tolerance after prolonged psychosocial stress), be on at least 25% sick leave or have marked functional impairment due to these symptoms, have a stable occupation or study situation, and be able to read and write Swedish. People with very long sick leave (more than two years), severe psychiatric conditions (such as severe depression, bipolar disorder, untreated PTSD, or psychosis), current substance abuse, or active suicidal ideation will not be included.\n\nPotential risks include temporary increases in distress, fatigue, or symptom awareness when working with emotions, behavior change, or work-related issues. Participants are monitored closely through weekly questionnaires and therapist contact. If risk for self-harm or serious deterioration is detected, a licensed psychologist will perform a risk assessment and, if needed, refer the participant to appropriate health care.\n\nThe hope is that this study will identify effective, scalable, and theory-based online treatments for clinical burnout and clarify whether adding structured vocational support improves long-term work outcomes.",[680,681,682],"Burnout","Clinical Burnout","Exhaustion Disorder",[684,685,680,686,687],"ACT","Online","Return To Work","Recovery","2025-11-26",{"date":616,"type":67},{"date":523,"type":23},{"date":441,"type":23},{"name":73,"class":74},{"id":694,"slug":695,"hasResults":12,"nctId":696,"briefTitle":697,"officialTitle":697,"acronym":698,"eligibilityCriteria":699,"healthyVolunteers":12,"sex":18,"minAge":700,"maxAge":701,"enrollmentInfo":702,"targetDuration":4,"studyType":24,"phases":704,"briefSummary":705,"conditions":706,"keywords":709,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":716,"lastUpdatePostDateStruct":717,"startDateStruct":719,"completionDateStruct":721,"leadSponsor":722,"locationsCount":108},"100608594","minimal-invasive-scoliosis-or-open-surgery-100608594","NCT07203586","Minimal Invasive Scoliosis or Open Surgery","MISCOS","Inclusion Criteria:\n\n* Written informed consent\n* Idiopathic scoliosis\n* Age between 10-25 years\n* Planed surgery: Posterior correction for scoliosis\n* Major curve Cobb angle 75 degrees or less\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Other diagnosis of scoliosis than \"idiopathic\"\n* Rigid curves that require posterior or three-column osteotomy\u002Fies\n* Previous surgery at the operated levels\n* BMI \\> 35\n* Psychological factors that make the patient unsuitable for inclusion in the study (e.g., substance abuse, developmental disability)","10 Years","25 Years",{"count":703,"type":23},180,[26],"Surgical treatment for idiopathic scoliosis usually involves open surgery from the back (posterior approach). This method corrects the curve and stabilizes the spine using screws and rods, followed by a fusion of the treated segments. The goal is to achieve the best possible alignment of the spine.\n\nThis type of surgery can be demanding for the body and often requires a longer hospital stay because of tissue damage and pain after the procedure. Traditionally, patients stayed in the hospital for up to a week or more.\n\nIn recent years, recovery programs such as ERAS (Enhanced Recovery After Surgery) have been introduced. These programs include better pain control, faster mobilization, and improved preparation before surgery. Thanks to these improvements, many patients can now go home one to two days after surgery instead of several days.\n\nThere has also been a development of minimally invasive surgery (MIS) techniques in spine surgery. These techniques aim to reduce tissue damage and blood loss compared to traditional open surgery. Smaller incisions can lead to less scarring, less pain, and potentially faster recovery. Because scoliosis surgery is complex, it is important to study whether MIS offers the same safety and benefits as traditional surgery.\n\nMinimally invasive surgery makes correct screw placement in the curved spine more challenging, as the usual anatomical landmarks are not fully exposed. To ensure accuracy, MIS often uses advanced technologies such as intraoperative 3D imaging or robotic-assisted surgery (RAS).\n\nThe purpose of this project is to evaluate whether MIS is as safe and effective as traditional open surgery. The study will compare both methods regarding the need for additional surgery, complications, infections, pain, and bone fusion after surgery. It will also examine hospital stay, degree of curve correction, accuracy of screw placement, changes in nerve function during surgery, blood loss, operation time, and patient-reported outcomes.\n\nMost existing studies on MIS in scoliosis are based on older or small patient series, and randomized controlled trials are lacking. This research will provide scientific evidence to guide future treatment choices. The aim is to determine whether MIS can deliver the same correction and safety as open surgery while reducing pain, blood loss, and recovery time. If proven effective, these techniques could improve recovery and quality of life for many scoliosis patients.",[707,708],"Idiopathic Adolescent Scoliosis","Idiopathic Juvenile Scoliosis",[710,711,712,713,714,715],"Idiopathic scoliosis","Minimally invasive scoliosis surgery","Traditional Open scoliosis surgical correction","Robotic assisted surgery (RAS)","Win-odds","non-inferiority randomised controlled trial","2025-09-29",{"date":718,"type":67},"2025-10-02",{"date":720,"type":23},"2025-10-15",{"date":330,"type":23},{"name":73,"class":74},""]